Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Eric, Darlison, Liz, Edwards, John, Elliott, Daisy, Fennell, D A, Popat, Sanjay, Rintoul, Robert C, Waller, David, Ali, Clinton, Bille, Andrea, Fuller, Liz, Ionescu, Andreea, Keni, Manjusha, Kirk, Alan, Koh, Pek, Lau, Kelvin, Mansy, Talal, Maskell, Nick A, Milton, Richard, Muthukumar, Dakshinamoorthy, Pope, Tony, Roy, Amy, Shah, Riyaz, Shamash, Jonathan, Tasigiannopoulos, Zacharias, Taylor, Paul, Treece, Sarah, Ashton, Kate, Harris, Rosie, Joyce, Katherine, Warnes, Barbara, Mills, Nicola, Stokes, Elizabeth A, Rogers, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467531/
https://www.ncbi.nlm.nih.gov/pubmed/32873681
http://dx.doi.org/10.1136/bmjopen-2020-038892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467531/
https://www.ncbi.nlm.nih.gov/pubmed/32873681
http://dx.doi.org/10.1136/bmjopen-2020-038892

Ejemplares similares